{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-028700","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2026-06-15T20:30:17+00:00","discovered_at":"2026-06-15T20:31:00.298462+00:00","generated_at":"2026-06-15T20:31:24.033063+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Dyadic highlights accelerated C1 platform interest amid Ebola preparedness and commercial adoption","bullets":["C1 platform can produce purified antigen or monoclonal antibody in ~15 days, says company.","Collaborations: Scripps Research (Ebola, hantaviruses); CEPI Ebola funding proposals; Fondazione Biotecnopolo di Siena (Ebola, hantavirus antibodies).","Commercial milestones: recombinant human albumin via Proliant Health; recombinant DNase I via Fermbox Bio; bovine chymosin via Inzymes.","Estimated addressable market >$25B across life sciences, food/nutrition, bioindustrial applications.","DYAI-100 clinical study showed C1-produced antigens were generally safe and well tolerated."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-028700","json":"https://secwatch.observer/filing/0001493152-26-028700.json","markdown":"https://secwatch.observer/filing/0001493152-26-028700.md","text":"https://secwatch.observer/filing/0001493152-26-028700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000149315226028700/0001493152-26-028700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000149315226028700/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:31:24.033063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}